{"id":15409,"date":"2025-11-17T18:21:26","date_gmt":"2025-11-17T12:51:26","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=15409"},"modified":"2025-11-17T18:28:17","modified_gmt":"2025-11-17T12:58:17","slug":"natco-pharma-q2-fy26-results","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/","title":{"rendered":"Natco Pharma Q2 FY26 Results: Net Profit Down 23.44% YoY; Revenue Slips 0.59%"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<p><a href=\"https:\/\/www.torusdigital.com\/stocks\/natco-pharma-ltd-share-price\">Natco Pharma<\/a> has released its financial results for the second quarter ended 30 September 2025 on 14<sup>th<\/sup> November 2025, reporting a softer performance compared to the same period last year. The company, which is a prominent player in India\u2019s <a href=\"https:\/\/www.torusdigital.com\/stocks\/sectors\/pharmaceuticals\">Pharmaceuticals sector<\/a>, saw its quarterly profitability affected by higher research and development (R&amp;D) spending, bioequivalence-related costs, and a one-time employee bonus. These factors collectively shaped the overall outcome for the quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Profit_and_Revenue_Performance\"><\/span><strong>Profit and Revenue Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Natco Pharma\u2019s consolidated net profit for Q2 FY26 stood at \u20b9517.9 crore, reflecting a 23.44% year-on-year decline from \u20b9676.5 crore reported in the previous fiscal\u2019s corresponding quarter.<\/p>\n<p>Revenue from operations was \u20b91,363 crore, a marginal dip compared to \u20b91,371.1 crore last year. Despite this, the company\u2019s total income rose to \u20b91,463 crore from \u20b91,434.9 crore, supported by an increase in other income to \u20b9100 crore from \u20b963.8 crore.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Higher_Expenses_Influence_Quarterly_Results\"><\/span><strong>Higher Expenses Influence Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Natco Pharma recorded total expenses of \u20b9849.3 crore, significantly higher than \u20b9616.7 crore in the same quarter last year.<\/p>\n<p>The company highlighted that this rise was driven by:<\/p>\n<ul>\n<li>Substantial R&amp;D spending, particularly on bioequivalence work<\/li>\n<li>A one-time employee bonus<\/li>\n<li>Additional business-related provisions<\/li>\n<\/ul>\n<p>These investments contributed to the reduced quarterly profit but underline the company\u2019s commitment to long-term product development and organisational expansion.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Segmental_Revenue_Breakdown\"><\/span><strong>Segmental Revenue Breakdown<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The formulations export segment remained the largest contributor, although it softened during the quarter:<\/p>\n<ul>\n<li><strong>Formulations export revenue:<\/strong> \u20b91,147 crore (down from \u20b91,211.3 crore)<\/li>\n<li><strong>API revenue:<\/strong> \u20b953.9 crore (up from \u20b949.6 crore)<\/li>\n<\/ul>\n<p>Revenue from crop health sciences grew notably to \u20b952.4 crore, compared with \u20b914.1 crore in the year-ago period.<\/p>\n<p>The contribution from domestic formulations and APIs saw marginal improvements, indicating steady demand within India.<\/p>\n<p><a href=\"https:\/\/torusdigital.go.link\/hgQeE\" target=\"_blank\" rel=\"noopener\"><br \/>\n<img decoding=\"async\" class=\"responsive-img\" src=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/07\/Desktop-1.jpg\" alt=\"\" \/><br \/>\n<\/a><\/p>\n<style>\n  .responsive-img {<br \/>    display: block;<br \/>    margin-left: auto;<br \/>    margin-right: auto;<br \/>    width: 100%;<br \/>    max-width: 900px;<br \/><\/style>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Announcement\"><\/span><strong>Dividend Announcement<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Board of Directors declared a second interim dividend of \u20b91.50 per equity share (face value \u20b92) for FY26, reinforcing the company\u2019s continued focus on shareholder value despite a moderated quarterly performance.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Corporate_Update_Demerger_of_Crop_Health_Sciences_Division\"><\/span><strong>Key Corporate Update: Demerger of Crop Health Sciences Division<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Natco Pharma confirmed that its Board has approved the incorporation of a wholly owned subsidiary in India, which will become the resulting company for the demerger of its Crop Health Sciences Division.<\/p>\n<p>This strategic move is expected to provide a clearer operational focus and create independent growth pathways for the division.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Market_Reaction\"><\/span><strong>Market Reaction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>On the day of the announcement, Natco Pharma\u2019s shares closed 1.33% lower at \u20b9815.10 each on the BSE.<\/p>\n<p><strong>Also Read:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/mrf-q2-fy26-results-out-profit-jumps-12-percent\/\">MRF Q2 FY26 Results: Profit Jumps 12% YoY, Revenue Rises 7.2%<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/marico-q2-fy26-results-out-31-percent-growth-in-revenue\/\">Marico Q2 FY26 Results: 31% Revenue Growth Despite a Slight 0.7% YoY Profit Decline<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/oil-india-q2-fy26-results-out-revenue-up-by-4-percent\/\">Oil India Q2 FY26 Results: Revenue Up 4% YoY While Profit Declines 43%; Interim Dividend Declared<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/tata-motos-pv-q2-fy26-results-show-soaring-profits\/\">Tata Motors PV Q2 FY26 Results: Profit Soars to \u20b976,170 Crore on One-Time Gain as Revenue Declines 13%<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/muthoot-finance-q2fy26-results\/\">Muthoot Finance Q2FY26 Results: Profit Jumps 87% as NII Rises 58%<\/a><\/li>\n<\/ul>\n<p><strong>Conclusion<\/strong><\/p>\n<p>Natco Pharma\u2019s Q2 FY26 performance reflects a temporary dip in profitability due to deliberate investments in R&amp;D, employee incentives, and business provisions. While revenue remained broadly stable, the company\u2019s emphasis on research-driven progress and its strategic decision to demerge the Crop Health Sciences Division signal a forward-looking approach.<\/p>\n<p>As Natco Pharma continues to strengthen its product pipeline and streamline its business verticals, the company remains positioned for sustainable growth in the evolving pharmaceutical landscape.<\/p>\n<p>To stay updated with daily\u202f<a href=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/\">financial results<\/a>, market insights, and developments, make sure to follow Torus Digital!<\/p>\n<p><span class=\"TextRun SCXW122739792 BCX0\" lang=\"EN-IN\" xml:lang=\"EN-IN\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW122739792 BCX0\" data-ccp-charstyle=\"normaltextrun\">\u202f\u202f\u202f\u202f<\/span><\/span><span class=\"EOP SCXW122739792 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--15409 \"  data-post-id=\"15409\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--half-highlight js-rmp-remove-half-star\"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results \">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">4.3<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">6<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated rmp-rating-widget__not-rated--hidden\">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fquarterly-results%2Fnatco-pharma-q2-fy26-results%2F&t=Natco+Pharma+Q2+FY26+Results%3A+Net+Profit+Down+23.44%25+YoY%3B+Revenue+Slips+0.59%25\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a href=\"\/\/twitter.com\/intent\/tweet?text=Natco+Pharma+Q2+FY26+Results%3A+Net+Profit+Down+23.44%25+YoY%3B+Revenue+Slips+0.59%25&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fquarterly-results%2Fnatco-pharma-q2-fy26-results%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a href=\"https:\/\/api.whatsapp.com\/send?text=Natco+Pharma+Q2+FY26+Results%3A+Net+Profit+Down+23.44%25+YoY%3B+Revenue+Slips+0.59%25 - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fquarterly-results%2Fnatco-pharma-q2-fy26-results%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fquarterly-results%2Fnatco-pharma-q2-fy26-results%2F&title=Natco+Pharma+Q2+FY26+Results%3A+Net+Profit+Down+23.44%25+YoY%3B+Revenue+Slips+0.59%25\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;] Natco Pharma has released its financial results for the second quarter ended 30 September 2025 on 14th November 2025, reporting a softer performance compared to the same period last year. The company, which is a prominent player in India\u2019s Pharmaceuticals sector, saw its quarterly profitability affected by higher research and","protected":false},"author":1,"featured_media":13457,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[281],"tags":[],"class_list":["post-15409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-quarterly-results"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Natco Pharma Q2 FY26 Results: Net Profit Falls to \u20b9517.9 Crore as Costs Rise<\/title>\n<meta name=\"description\" content=\"Natco Pharma reports a 23% year-on-year decline in Q2 FY26 consolidated net profit to \u20b9517.9 crore, impacted by higher R&amp;D expenses and a one-time employee bonus. Learn how revenue, segment performance, and key business developments shaped this quarter.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natco Pharma Q2 FY26 Results: Net Profit Falls to \u20b9517.9 Crore as Costs Rise\" \/>\n<meta property=\"og:description\" content=\"Natco Pharma reports a 23% year-on-year decline in Q2 FY26 consolidated net profit to \u20b9517.9 crore, impacted by higher R&amp;D expenses and a one-time employee bonus. Learn how revenue, segment performance, and key business developments shaped this quarter.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T12:51:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T12:58:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Sammaan-Capital-Ltd-Q1-results-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natco Pharma Q2 FY26 Results: Net Profit Falls to \u20b9517.9 Crore as Costs Rise","description":"Natco Pharma reports a 23% year-on-year decline in Q2 FY26 consolidated net profit to \u20b9517.9 crore, impacted by higher R&D expenses and a one-time employee bonus. Learn how revenue, segment performance, and key business developments shaped this quarter.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/","og_locale":"en_US","og_type":"article","og_title":"Natco Pharma Q2 FY26 Results: Net Profit Falls to \u20b9517.9 Crore as Costs Rise","og_description":"Natco Pharma reports a 23% year-on-year decline in Q2 FY26 consolidated net profit to \u20b9517.9 crore, impacted by higher R&D expenses and a one-time employee bonus. Learn how revenue, segment performance, and key business developments shaped this quarter.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/","og_site_name":"Blog","article_published_time":"2025-11-17T12:51:26+00:00","article_modified_time":"2025-11-17T12:58:17+00:00","og_image":[{"width":1440,"height":465,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Sammaan-Capital-Ltd-Q1-results-1.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/","url":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/","name":"Natco Pharma Q2 FY26 Results: Net Profit Falls to \u20b9517.9 Crore as Costs Rise","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Sammaan-Capital-Ltd-Q1-results-1.webp","datePublished":"2025-11-17T12:51:26+00:00","dateModified":"2025-11-17T12:58:17+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Natco Pharma reports a 23% year-on-year decline in Q2 FY26 consolidated net profit to \u20b9517.9 crore, impacted by higher R&D expenses and a one-time employee bonus. Learn how revenue, segment performance, and key business developments shaped this quarter.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Sammaan-Capital-Ltd-Q1-results-1.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Sammaan-Capital-Ltd-Q1-results-1.webp","width":1440,"height":465},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/natco-pharma-q2-fy26-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"Quarterly Results","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/quarterly-results\/"},{"@type":"ListItem","position":3,"name":"Natco Pharma Q2 FY26 Results: Net Profit Down 23.44% YoY; Revenue Slips 0.59%"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=15409"}],"version-history":[{"count":2,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15409\/revisions"}],"predecessor-version":[{"id":15412,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15409\/revisions\/15412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/13457"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=15409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=15409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=15409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}